Shenzhen - Delayed Quote CNY

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ)

Compare
69.11 -1.14 (-1.62%)
At close: December 27 at 3:04:19 PM GMT+8
Loading Chart for 300832.SZ
DELL
  • Previous Close 70.25
  • Open 66.19
  • Bid 69.06 x --
  • Ask 69.20 x --
  • Day's Range 69.00 - 70.90
  • 52 Week Range 58.31 - 97.20
  • Volume 2,719,961
  • Avg. Volume 5,607,844
  • Market Cap (intraday) 54.301B
  • Beta (5Y Monthly) -0.43
  • PE Ratio (TTM) 29.28
  • EPS (TTM) 2.36
  • Earnings Date --
  • Forward Dividend & Yield 1.00 (1.53%)
  • Ex-Dividend Date May 15, 2024
  • 1y Target Est 85.65

Shenzhen New Industries Biomedical Engineering Co., Ltd., a bio-medical company, engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in the People's Republic of China and internationally. It offers immunoassay, biochemistry/electrolyte, molecular diagnostics, point of care testing, lab automation, and integrated system, products. The company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China.

www.snibe.com

2,627

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300832.SZ

View More

Performance Overview: 300832.SZ

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300832.SZ
10.46%
SSE Composite Index
14.29%

1-Year Return

300832.SZ
7.50%
SSE Composite Index
17.29%

3-Year Return

300832.SZ
59.14%
SSE Composite Index
6.02%

5-Year Return

300832.SZ
248.58%
SSE Composite Index
13.06%

Compare To: 300832.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300832.SZ

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    54.30B

  • Enterprise Value

    51.72B

  • Trailing P/E

    29.34

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.24

  • Price/Book (mrq)

    6.69

  • Enterprise Value/Revenue

    11.66

  • Enterprise Value/EBITDA

    24.49

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    41.72%

  • Return on Assets (ttm)

    14.87%

  • Return on Equity (ttm)

    24.32%

  • Revenue (ttm)

    4.44B

  • Net Income Avi to Common (ttm)

    1.85B

  • Diluted EPS (ttm)

    2.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.59B

  • Total Debt/Equity (mrq)

    0.06%

  • Levered Free Cash Flow (ttm)

    967.3M

Research Analysis: 300832.SZ

View More

People Also Watch